188 related articles for article (PubMed ID: 35022448)
1. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.
Sands E; Kivitz A; DeHaan W; Leung SS; Johnston L; Kishimoto TK
Nat Commun; 2022 Jan; 13(1):272. PubMed ID: 35022448
[TBL] [Abstract][Full Text] [Related]
2. Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Kishimoto TK
Front Immunol; 2020; 11():969. PubMed ID: 32508839
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110).
Kivitz A; DeHaan W; Azeem R; Park J; Rhodes S; Inshaw J; Leung SS; Nicolaou S; Johnston L; Kishimoto TK; Traber PG; Sands E; Choi H
Rheumatol Ther; 2023 Aug; 10(4):825-847. PubMed ID: 37069364
[TBL] [Abstract][Full Text] [Related]
4. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
Baraf HSB; Khanna PP; Kivitz AJ; Strand V; Choi HK; Terkeltaub R; Dalbeth N; DeHaan W; Azeem R; Traber PG; Keenan RT
Rheumatology (Oxford); 2024 Apr; 63(4):1058-1067. PubMed ID: 37449908
[TBL] [Abstract][Full Text] [Related]
5. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
[TBL] [Abstract][Full Text] [Related]
6. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
[TBL] [Abstract][Full Text] [Related]
7. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
Sherman MR; Saifer MG; Perez-Ruiz F
Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
[TBL] [Abstract][Full Text] [Related]
8. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
Kishimoto TK; Ferrari JD; LaMothe RA; Kolte PN; Griset AP; O'Neil C; Chan V; Browning E; Chalishazar A; Kuhlman W; Fu FN; Viseux N; Altreuter DH; Johnston L; Maldonado RA
Nat Nanotechnol; 2016 Oct; 11(10):890-899. PubMed ID: 27479756
[TBL] [Abstract][Full Text] [Related]
9. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles.
Ilyinskii PO; Roy CJ; LePrevost J; Rizzo GL; Kishimoto TK
Front Immunol; 2021; 12():637469. PubMed ID: 34113339
[TBL] [Abstract][Full Text] [Related]
11. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Bomalaski JS; Clark MA
Curr Rheumatol Rep; 2004 Jun; 6(3):240-7. PubMed ID: 15134605
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
[TBL] [Abstract][Full Text] [Related]
13. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
Chua CC; Greenberg ML; Viau AT; Nucci M; Brenckman WD; Hershfield MS
Ann Intern Med; 1988 Jul; 109(2):114-7. PubMed ID: 3289428
[TBL] [Abstract][Full Text] [Related]
14. Oral Delivery of Nanoparticles Carrying Ancestral Uricase Enzyme Protects against Hyperuricemia in Knockout Mice.
Tran L; Das S; Zhao L; Finn MG; Gaucher EA
Biomacromolecules; 2023 May; 24(5):2003-2008. PubMed ID: 37126604
[TBL] [Abstract][Full Text] [Related]
15. Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia.
Xiong H; Zhou Y; Zhou Q; He D; Deng X; Sun Q; Zhang J
Nanomedicine; 2016 Aug; 12(6):1557-66. PubMed ID: 27013130
[TBL] [Abstract][Full Text] [Related]
16. ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia.
Ilyinskii PO; Michaud AM; Rizzo GL; Roy CJ; Leung SS; Elkins SL; Capela T; Chowdhury A; Li L; Chandler RJ; Manoli I; Andres-Mateos E; Johnston LPM; Vandenberghe LH; Venditti CP; Kishimoto TK
Mol Ther Methods Clin Dev; 2021 Sep; 22():279-292. PubMed ID: 34485611
[TBL] [Abstract][Full Text] [Related]
17. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
Szczurek P; Mosiichuk N; Woliński J; Yatsenko T; Grujic D; Lozinska L; Pieszka M; Święch E; Pierzynowski SG; Goncharova K
PLoS One; 2017; 12(6):e0179195. PubMed ID: 28594873
[TBL] [Abstract][Full Text] [Related]
18. Improved biological properties and hypouricemic effects of uricase from Candida utilis loaded in novel alkaline enzymosomes.
Tan QY; Zhang JQ; Wang N; Yang H; Li X; Xiong HR; Wu JY; Zhao CJ; Wang H; Yin HF
Int J Nanomedicine; 2012; 7():3929-38. PubMed ID: 22915844
[TBL] [Abstract][Full Text] [Related]
19. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Cammalleri L; Malaguarnera M
Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
[TBL] [Abstract][Full Text] [Related]
20. Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase.
Abuchowski A; Karp D; Davis FF
J Pharmacol Exp Ther; 1981 Nov; 219(2):352-4. PubMed ID: 7288624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
